+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
UNIHEALTH

Unihealth Hospitals Share Price

 
Stock touched all time high

 

Unihealth Hospitals live price: ₹716.5. It opened at ₹748 vs previous close ₹720; intraday high/low: ₹748/₹711. The 50 & 200 DMA stand at ₹528.01/₹376.44.

Unihealth Hospitals Performance

  • Today's Low
  • ₹711
  • Today's High
  • ₹748
  • 52 Week Low
  • ₹134
  • 52 Week High
  • ₹748
  • Open Price₹748
  • Previous Close₹720
  • Volume13,500
  • 50 DMA₹528.01
  • 100 DMA₹459.40
  • 200 DMA₹376.44

Unihealth Hospitals Chart

Investment Returns

  • Over 1 Month + 55.05%
  • Over 3 Month + 73.19%
  • Over 6 Month + 131.58%
  • Over 1 Year + 312.97%

Smart Investing Starts Here Start SIP with Unihealth Hospitals for Steady Growth!

Invest Now

Unihealth Hospitals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 43.8
  • PEG Ratio
  • -
  • Market Cap Cr
  • 1,132
  • P/B Ratio
  • 8.2
  • Average True Range
  • 31.62
  • EPS
  • 16.25
  • Dividend Yield
  • 0
  • MACD Signal
  • 47.29
  • RSI
  • 80.26
  • MFI
  • 89.55

Latest Stock News Updates

Unihealth Consultancy IPO: What latest GMP signals as focus shifts to share allotment

As the subscription period for Unihealth Consultancy IPO has ended, the investors who have bid for the public issue, will now focus on share allotment. Unihealth Consultancy IPO allotment is likely to be finalised on September 15, Friday.

Unihealth Hospitals Financials

Unihealth Hospitals Technicals

EMA & SMA

Current Price
₹716.50
-3.5 (-0.49%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹604.00
  • 50 Day
  • ₹528.00
  • 100 Day
  • ₹459.40
  • 200 Day
  • ₹376.40

Resistance and Support

725.2 Pivot Speed
  • R3 775.90
  • R2 761.90
  • R1 739.20
  • S1 702.50
  • S2 688.50
  • S3 665.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Unihealth Hospitals Ltd has an operating revenue of Rs. 187.58 Cr. on a trailing 12-month basis. An annual revenue growth of 135% is outstanding, Pre-tax margin of 35% is great, ROE of 18% is exceptional. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 38% and 104% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 35% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 98 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 3 indicates it belongs to a strong industry group of Medical-Managed Care and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Unihealth Hospitals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-03 To consider Fund Raising
2026-05-29 Audited Results
2025-11-14 Quarterly Results
2025-05-23 Audited Results
2025-03-10 To consider Fund Raising

Unihealth Hospitals Shareholding Pattern

69.53%
0%
25.02%
5.45%

Unihealth Hospitals FAQs

Unihealth Hospitals share price is ₹716 As on 09 July, 2026 | 18:12

The Market Cap of Unihealth Hospitals is ₹1132.1 Cr As on 09 July, 2026 | 18:12

The P/E ratio of Unihealth Hospitals is 43.8 As on 09 July, 2026 | 18:12

The PB ratio of Unihealth Hospitals is 8.2 As on 09 July, 2026 | 18:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23